Bladder cancer in the elderly patient: challenges and solutions

References

• Surveillance Research ProgramSEER Stat Fact Sheets: BladderNational Cancer Institute2013 Available from: http://seer.cancer.gov/statfacts/html/urinb.htmlAccessed April 12, 2015
   Google Scholar
• International Bladder Cancer Nomogram ConsortiumBochnerBHKattanMWVoraKCPostoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancerJ Clin Oncol200624243967397216864855
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrEinhornLHElsonPJA randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyJ Clin Oncol1992107106610731607913
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• NovaraGCattoJWWilsonTSystematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomyEur Urol201567337640125560798
   PubMed Web of Science ®Google Scholar
• ProutGRJrWesleyMNYancikRRiesLAHavlikRJEdwardsBKAge and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based studyCancer200510481638164716130136
   PubMed Web of Science ®Google Scholar
• SchiffmannJGandagliaGLarcherAContemporary 90-day mortality rates after radical cystectomy in the elderlyEur J Surg Oncol201440121738174525454826
   PubMed Web of Science ®Google Scholar
• FaireyAChetnerMMetcalfeJAssociations among age, comorbidity and clinical outcomes after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy DatabaseJ Urol2008180112813418485375
   PubMed Web of Science ®Google Scholar
• NielsenMEShariatSFKarakiewiczPIAdvanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomyEur Urol200751369970617113703
   PubMed Web of Science ®Google Scholar
• FroehnerMBrausiMAHerrHWMutoGStuderUEComplications following radical cystectomy for bladder cancer in the elderlyEur Urol200956344345419481861
   PubMed Web of Science ®Google Scholar
• GilbertSMLaiJSaigalCSGoreJLUrologic Diseases in America ProjectDownstream complications following urinary diversionJ Urol2013190391692223499749
   PubMed Web of Science ®Google Scholar
• SogniFBrausiMFreaBMorbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancerUrology200871591992318355900
   PubMed Web of Science ®Google Scholar
• ClarkPESteinJPGroshenSGRadical cystectomy in the elderly: comparison of clinical outcomes between younger and older patientsCancer20051041364315912515
   PubMed Web of Science ®Google Scholar
• TangKLiHXiaDLaparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studiesPLoS One201495e9566724835573
   PubMed Web of Science ®Google Scholar
• LinTFanXZhangCA prospective randomised controlled trial of laparoscopic vs open radical cystectomy for bladder cancer: perioperative and oncologic outcomes with 5-year follow-upBr J Cancer2014110484284924407192
   PubMed Web of Science ®Google Scholar
• NixJSmithAKurpadRNielsenMEWallenEMPruthiRSProspective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic resultsEur Urol201057219620119853987
   PubMed Web of Science ®Google Scholar
• NiegischGAlbersPRabenaltRPerioperative complications and oncological safety of robot-assisted (RARC) vs open radical cystectomy (ORC)Urol Oncol201432796697425017695
   PubMed Web of Science ®Google Scholar
• NguyenDPAwamlhBACharles OsterbergEPostoperative complications and short-term oncological outcomes of patients aged ≥80 years undergoing robot-assisted radical cystectomyWorld J Urol11202014 Epub ahead of print
   Web of Science ®Google Scholar
• ClaymanRHShipleyWUGalland-GirodetSOutcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiationInt J Radiat Oncol Biol Phys2013872S83
   Web of Science ®Google Scholar
• GrayPJFedewaSAShipleyWUUse of potentially curative therapies for muscle-invasive bladder cancer in the united states: results from the National Cancer DatabaseEur Urol201363582382923200811
   PubMed Web of Science ®Google Scholar
• ChenRCShipleyWUEfstathiouJAZietmanALTrimodality bladder preservation therapy for muscle-invasive bladder cancerJ Natl Compr Canc Netw201311895296023946174
   PubMed Web of Science ®Google Scholar
• JamesNDHussainSAHallERadiotherapy with or without chemotherapy in muscle-invasive bladder cancerN Engl J Med2012366161477148822512481
   PubMed Web of Science ®Google Scholar
• MakRHHuntDShipleyWULong-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233J Clin Oncol201432343801380925366678
   PubMed Web of Science ®Google Scholar
• EfstathiouJABaeKShipleyWULate pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06J Clin Oncol200927254055406119636019
   PubMed Web of Science ®Google Scholar
• ZietmanALSaccoDSkowronskiUOrgan conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivorsJ Urol200317051772177614532773
   PubMed Web of Science ®Google Scholar
• DuchesneGMBolgerJJGriffithsGOA randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of Medical Research Council trial BA09Int J Radiat Oncol Biol Phys200047237938810802363
   PubMed Web of Science ®Google Scholar
• KoulouliasVToliaMKolliarakisNSiatelisAKelekisNEvaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancerInt Braz J Urol2013391778223489500
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis CollaborationNeoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaborationEur Urol200548220220515939524
   PubMed Web of Science ®Google Scholar
• GrossmanHBNataleRBTangenCMNeoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerN Engl J Med2003349985986612944571
   PubMed Web of Science ®Google Scholar
• SternbergCNSkonecznaIAKerstJMFinal results of EORTC Intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladderJ Clin Oncol2014325 Suppl Abstr 4500
   Google Scholar
• ClarkPEAgarwalNBiagioliMCBladder cancer (version 2.2014) Available from: www.nccn.orgAccessed April 11, 2015
   Google Scholar
• RajGVKaravadiaSSchlomerBContemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancerCancer2011117227628220830767
   PubMed Web of Science ®Google Scholar
• RehmanSCraneADinRUnderstanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancerUrology20138261370137524125689
   PubMed Web of Science ®Google Scholar
• MontgomeryJSMillerDCWeizerAZQuality indicators in the management of bladder cancerJ Natl Compr Canc Netw201311449250023584349
   PubMed Web of Science ®Google Scholar
• HurriaATogawaKMohileSGPredicting chemotherapy toxicity in older adults with cancer: a prospective multicenter studyJ Clin Oncol201129253457346521810685
   PubMed Web of Science ®Google Scholar
• HutchinsLFUngerJMCrowleyJJColtmanCAJrAlbainKSUnder-representation of patients 65 years of age or older in cancer-treatment trialsN Engl J Med1999341272061206710615079
   PubMed Web of Science ®Google Scholar
• GalskyMDHow I treat bladder cancer in elderly patientsJ Geriatr Oncol2015611725482022
   PubMed Web of Science ®Google Scholar
• SonpavdeGWatsonDTourtellottMAdministration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the communityClin Genitourin Cancer20121011522340630
   PubMed Web of Science ®Google Scholar
• GalskyMDChenGJOhWKComparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinomaAnn Oncol201223240641021543626
   PubMed Web of Science ®Google Scholar
• GalskyMDHahnNMRosenbergJTreatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapyJ Clin Oncol201129172432243821555688
   PubMed Web of Science ®Google Scholar
• GalskyMDHahnNMRosenbergJA consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapyLancet Oncol201112321121421376284
   PubMed Web of Science ®Google Scholar
• ChauCWheaterMGeldartTCrabbSJClinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patientsEur J Cancer Care (Engl)201524215516225620269
   PubMed Web of Science ®Google Scholar
• GalskyMDKregeSLinCCCisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancerUrol Oncol201432130.e1530.e2123428534
   PubMed Web of Science ®Google Scholar
• von der MaaseHHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III studyJ Clin Oncol200018173068307711001674
   PubMed Web of Science ®Google Scholar
• De SantisMBellmuntJMeadGRandomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986J Clin Oncol201230219119922162575
   PubMed Web of Science ®Google Scholar
• SonpavdeGGalskyMDLatiniDChenGJCisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancerClin Genitourin Cancer2014122717324355418
   PubMed Web of Science ®Google Scholar
• McCaffreyJAHiltonSMazumdarMPhase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinomaJ Clin Oncol1997155185318579164195
   PubMed Web of Science ®Google Scholar
• VaughnDJBroomeCMHussainMGutheilJCMarkowitzABPhase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancerJ Clin Oncol200220493794011844814
   PubMed Web of Science ®Google Scholar
• SweeneyCJRothBJKabbinavarFFPhase II study of pemetrexed for second-line treatment of transitional cell cancer of the urotheliumJ Clin Oncol200624213451345716849761
   PubMed Web of Science ®Google Scholar
• WitteRSElsonPBonoBEastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinomaJ Clin Oncol19971525895939053481
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular characterization of urothelial bladder carcinomaNature2014507749231532224476821
   PubMed Web of Science ®Google Scholar
• ChoiWPortenSKimSIdentification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyCancer Cell201425215216524525232
   PubMed Web of Science ®Google Scholar
• DamrauerJSHoadleyKAChismDDIntrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biologyProc Natl Acad Sci U S A201411183110311524520177
   PubMed Web of Science ®Google Scholar
• IyerGHanrahanAJMilowskyMIGenome sequencing identifies a basis for everolimus sensitivityScience2012338610422122923433
   PubMed Web of Science ®Google Scholar
• WagleNGrabinerBCVan AllenEMActivating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibCancer Discov20144554655324625776
   PubMed Web of Science ®Google Scholar
• IyerGAl-AhmadieHSchultzNPrevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancerJ Clin Oncol201331253133314023897969
   PubMed Web of Science ®Google Scholar
• RossJSWangKAl-RohilRNAdvanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapyMod Pathol201427227128023887298
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• PowlesTEderJPFineGDMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature2014515752855856225428503
   PubMed Web of Science ®Google Scholar
• McDermottJJimenoAPembrolizumab: PD-1 inhibition as a therapeutic strategy in cancerDrugs Today (Barc)201551172025685857
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• FungCPandyaCGuancialEImpact of bladder cancer on health related quality of life in 1,476 older Americans: a cross-sectional studyJ Urol2014192369069524704007
   PubMed Web of Science ®Google Scholar
• MessingEMMadebRFengCGrade and stage at presentation do not predict mortality in patients with bladder cancer who survive their diseaseJ Clin Oncol200927152443244919332735
   PubMed Web of Science ®Google Scholar
• NoonAPAlbertsenPCThomasFRosarioDJCattoJWCompeting mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patientsBr J Cancer201310871534154023481180
   PubMed Web of Science ®Google Scholar
• KarvinenKHCourneyaKSNorthSVennerPAssociations between exercise and quality of life in bladder cancer survivors: a population-based studyCancer Epidemiol Biomarkers Prev200716598499017507626
   PubMed Web of Science ®Google Scholar
• WildesTMRuweAPFournierCGeriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancerJ Geriatr Oncol20134322723423795224
   PubMed Web of Science ®Google Scholar
• ApoloABHoffmanVKaagMGSummary of the 8th Annual Bladder Cancer Think Tank: collaborating to move research forwardUrol Oncol2015332536425065704
   PubMed Web of Science ®Google Scholar
• BottemanMFPashosCLHauserRSLaskinBLRedaelliAQuality of life aspects of bladder cancer: a review of the literatureQual Life Res200312667568814516177
   PubMed Web of Science ®Google Scholar
• ParkinsonJPKonetyBRHealth related quality of life assessments for patients with bladder cancerJ Urol20041726 Pt 12130213615538218
   PubMed Web of Science ®Google Scholar
• AaronsonNKAhmedzaiSBergmanBThe European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst19938553653768433390
   PubMed Web of Science ®Google Scholar
• CellaDFTulskyDSGrayGThe Functional Assessment of Cancer Therapy scale: development and validation of the general measureJ Clin Oncol19931135705798445433
   PubMed Web of Science ®Google Scholar
• SingerSZieglerCSchwalenbergTHinzAGotzeHSchulteTQuality of life in patients with muscle invasive and non-muscle invasive bladder cancerSupport Care Cancer20132151383139323238655
   PubMed Web of Science ®Google Scholar
• MohamedNEDiefenbachMAGoltzHHMuscle invasive bladder cancer: from diagnosis to survivorshipAdv Urol2012201214213522924038
   PubMedGoogle Scholar
• AllareddyVKennedyJWestMMKonetyBRQuality of life in long-term survivors of bladder cancerCancer2006106112355236216649218
   PubMed Web of Science ®Google Scholar
• GilbertSMWoodDPDunnRLMeasuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI)Cancer200710991756176217366596
   PubMed Web of Science ®Google Scholar
• ReeveBBPotoskyALSmithAWImpact of cancer on health-related quality of life of older AmericansJ Natl Cancer Inst20091011286086819509357
   PubMed Web of Science ®Google Scholar
• NormanGRSloanJAWyrwichKWInterpretation of changes in health-related quality of life: the remarkable universality of half a standard deviationMed Care200341558259212719681
   PubMed Web of Science ®Google Scholar
• RoaldsenMAarsaetherEKnutsenTPatelHRStrategies to improve quality of life in bladder cancer patientsExpert Rev Pharmacoecon Outcomes Res201414453754424813931
   PubMed Web of Science ®Google Scholar
• DaleW“Staging the aging” when considering androgen deprivation therapy for older men with prostate cancerJ Clin Oncol200927213420342219506150
   PubMed Web of Science ®Google Scholar
• WalterLCCovinskyKECancer screening in elderly patients: a framework for individualized decision makingJAMA2001285212750275611386931
   PubMed Web of Science ®Google Scholar
• Goossens-LaanCALeliveldAMVerhoevenRHEffects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancerInt J Cancer2014135490591224420527
   PubMed Web of Science ®Google Scholar
• MohileSDaleWHurriaAGeriatric oncology research to improve clinical careNat Rev Clin Oncol201291057157822825377
   PubMed Web of Science ®Google Scholar
• KoroukianSMXuFBakakiPMDiaz-InsuaMToweTPOwusuCComorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancerJ Gerontol A Biol Sci Med Sci201065332232920018824
   PubMed Web of Science ®Google Scholar
• PsutkaSPCarrascoASchmitGDSarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortalityCancer2014120182910291824840856
   PubMed Web of Science ®Google Scholar
• PalSKKatheriaVHurriaAEvaluating the older patient with cancer: understanding frailty and the geriatric assessmentCA Cancer J Clin201060212013220173172
   PubMed Web of Science ®Google Scholar
• HurriaABrownerISCohenHJSenior adult oncologyJ Natl Compr Canc Netw201210216220922308515
   PubMed Web of Science ®Google Scholar
• HurriaAGuptaSZaudererMDeveloping a cancer-specific geriatric assessment: a feasibility studyCancer200510491998200516206252
   PubMed Web of Science ®Google Scholar
• HurriaACohenHJExtermannMGeriatric oncology research in the cooperative groups: a report of a SIOG special meetingJ Geriatr Oncol201011404421218146
   PubMed Web of Science ®Google Scholar
• BalducciLExtermannMManagement of the frail person with advanced cancerCrit Rev Oncol Hematol200033214314810737376
   PubMed Web of Science ®Google Scholar
• GillTMBakerDIGottschalkMA prehabilitation program for physically frail community-living older personsArch Phys Med Rehabil200384339440412638108
   PubMed Web of Science ®Google Scholar
• HewittJMougSJMiddletonMPrevalence of frailty and its association with mortality in general surgeryAm J Surg2015209225425925173599
   PubMed Web of Science ®Google Scholar
• KetelaarsLPottelLLyckeMUse of the Freund clock drawing test within the Mini-Cog as a screening tool for cognitive impairment in elderly patients with or without cancerJ Geriatr Oncol20134217418224071542
   PubMed Web of Science ®Google Scholar
• MohileSGXianYDaleWAssociation of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiariesJ Natl Cancer Inst2009101171206121519638506
   PubMedGoogle Scholar